Clene Inc.

CLNN

NASDAQ

Healthcare

Biotechnology

Salt Lake City, UT, US75 employeesclene.com

$5.19

+0.30(6.13%)

Mkt Cap $52M

$2.37

$12.50

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Product (73.3%), Royalty (26.7%).

8-K

Clene Inc. filed an 8-K on March 12, 2026, under Item 2.02 announcing full year results via Exhibit 99.1 press release, which is not deemed 'filed' under Section 18 of the Exchange Act. The filing includes Item 9.01 for financial statements and exhibits.

$52M

Market Cap

$202.9K

Revenue

-$27M

Net Income

Employees75

Fundamentals

How The Business Makes Money

Revenue by Segment

Product73.3%($1M)

Royalty26.7%($522.0K)

Activity

What Changed Recently

Financial Results

Mar 11, 2026

, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended,

Material Agreement

Jan 12, 2026

Entry into a Material Definitive Agreement. Securities Purchase Agreement On January 8, 2026, Clene Inc. (the “Company”) entered into a securities purchase agre

Other Event

Feb 23, 2026

, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended,

Other Event

Jan 11, 2026

Other Events. On January 12, 2026, Clene Inc. issued a press release announcing additional CNM-Au8 ® biomarker data supporting a potential new drug application

Peer Companies

Company	Price	Change	Market Cap	P/E
OVIDOvid Therapeutics Inc.	$2.19	+1.62%	$332M	-12.0
STTKShattuck Labs, Inc.	$6.43	+2.96%	$308M	-13.0
CNTXContext Therapeutics Inc.	$2.73	+3.02%	$251M	-10.9
MGNXMacroGenics, Inc.	$3.06	+5.69%	$195M	-2.5
ZNTLZentalis Pharmaceuticals,...	$2.63	+2.14%	$186M	-1.2
CNTBConnect Biopharma Holding...	$3.00	+10.48%	$168M	-4.5
WHWKWhitehawk Therapeutics In...	$3.50	-1.13%	$165M	-12.3
ORMPOramed Pharmaceuticals In...	$3.43	+1.18%	$139M	3.4

Analyst View

Company Profile

CIK0001822791

ISINUS1856342019

CUSIP185634102

Phone801 676 9695

Address6550 South Millrock Drive, Salt Lake City, UT, 84121, US

SEC EDGAR